Eleven-Year Outcome of Patients with Prostate Cancers Diagnosed During Screening After Initial Negative Sextant Biopsies

European Urology

Volumn 57, Issue 2, 2010, Pages 256-266

  Schröder, Fritz H ^a   van den Bergh, Roderick C N ^a   Wolters, Tineke ^a   van Leeuwen, Pim J ^a   Bangma, Chris H ^a   van der Kwast, Theo H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Progression; Prostate cancer; Prostate cancer mortality; PSA; Screening; Sextant prostate biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY;

AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 72149085443     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.10.031     Document Type: Article

References (35)

1. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
2. Roobol M.J., Kerkhof M., Schröder F.H., et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomized study of Screening for Prostate Cancer (ERSPC). Eur Urol 56 (2009) 584-591
3. Terris M.K., Freiha F.S., McNeal J.E., and Stamey T.A. Efficacy of transrectal ultrasound for identification of clinically undetected prostate cancer. J Urol 146 (1991) 78-83
4. Eskew L.A., Bare R.L., and McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157 (1997) 207-208
5. De la Taille A., Antiphon P., Salomon L., et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 61 (2003) 1181-1186
6. Epstein J.I., Walsh P.C., and Carter H.B. Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 57 (2001) 1112-1116
7. Neill M.G., Toi A., Lochwood G.A., Evans A., Tammsalu L., and Fleshner N.E. Systematic lateral prostate biopsy-are the benefits worth the costs?. J Urol 179 (2008) 1321-1326
8. Presti Jr. J.C., Chang J.J., Bhargava V., and Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 163 (2000) 179-180
9. Gore J.L., Shariat S.F., Miles B.J., et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 165 (2001) 1554-1559
10. Paul R., Schöler S., van Randenborgh H., et al. Optimization of prostatic biopsy: a prospective randomized trial comparing the sextant biopsy with a 10-core biopsy. Impact of prostatic region of sampling. Urol Int 74 (2005) 203-208
11. Keetch D.W., Catalona W.J., and Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151 (1994) 1571-1574
12. Roehrborn C.G., Pickens G.J., and Sanders J.S. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnosis and prostate specific antigen levels. Urology 47 (1996) 347-352
13. Fleshner N.E., O'Sullivan M., and Fair W.R. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 158 (1997) 508-509
14. Rietbergen J.B., Kruger A.E., Hoedemaeker R.F., Bangma C.H., Kirkels W.J., and Schröder F.H. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men: clinical and pathological features of detected cancer. J Urol 160 (1998) 2121-2125
15. Letran J.L., Meyer G.E., Loberiza F.R., and Brawer M.K. The effect of prostate volume on the yield of needle biopsy. J Urol 160 (1998) 1718-1721
16. Djavan B., Zlotta A.R., Remzi M., et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1.051 men. J Urol 163 (2000) 1144-1148
17. O'Dowd G.J., Miller M.C., Orozco R., and Veltri R.W. Analysis or repeated biopsies results within 1 year after cancer diagnosis. Urology 55 (2000) 553-559
18. Lujan M., Paez A., Santonja C., Pascual T., Fernandez I., and Berenguer A. Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions. Prostate Cancer Prostatic Dis 7 (2004) 238-242
19. Stewart C.S., Leibovich B.C., Weaver A.L., and Lieber M.M. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166 (2001) 86-91
20. Lane B.R., Zippe C.D., Abouassaly R., Schoenfield L., Magi-Galluzzi C., and Jones J.S. Saturation technique does not decrease cancer detection during follow-up after initial prostate biopsy. J Urol 179 (2008) 1746-1750
21. Park S.J., Miyake H., Hara I., and Eto H. Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int J Urol 10 (2003) 68-71
22. Ciatto S., Lombardi C., Rubeca T., and Zappa M. Predictors of random sextant biopsy outcome in screened men with PSA >4 ng/ml and a negative sextant biopsy at previous screening. Experience in a population-based screening program in Florence. Int J Biol Markers 19 (2004) 89-92
23. Catalona W.J., Beiser J.A., and Smith D.S. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 158 (1997) 2162-2167
24. Durkan G.C., and Greene D.R. Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy?. BJU Int 83 (1999) 34-38
25. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assoc 53 (1958) 457-481
26. Han M, Walsh PC, Catalona WJ, et al. Updated recurrence free-survival prediction model following radical prostatectomy. J Urol (abstract issue) 2007, abstract 327.
27. Brawn P.N., Ayala A.G., von Eschenbach A.C., Hussey D.H., and Johnson D.E. Histologic grading study of prostate adenocarcinoma: the development of a new system and comparison with other methods-a preliminary study. Cancer 49 (1982) 525-532
28. De Koning H.J., Blom J., Merkelbach J.W., et al. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 92 (2003) 71-78
29. Scattoni V., Zlotta A., Montironi R., Schulman C., Rigatti P., and Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 52 (2007) 1309-1322
30. Vis A.N., Boerma M.O., Ciatto S., Hoedemaeker R.F., Schröder F.H., and van der Kwast T.H. Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 56 (2000) 617-621
31. Ficarra V., Novella G., Novara G., et al. The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. Eur Urol 48 (2005) 932-937
32. Gann P.H., Hennekes C.H., and Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 (1995) 289-294
33. Postma R., van Leenders A.G.J.L.H., Roobol M.J., Schröder F.H., and van der Kwast T.H. Tumour features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 50 (2006) 70-75
34. Schröder F.H., Bangma C.H., and Roobol M.J. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 53 (2008) 901-908
35. Heidenreich A., Aus G., Bolla M., et al. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80